Acta Médica Portuguesa
May 2, 2025
Pedro Mota, Jorge Encantado, Laura C. Carvalho et al.
1 citation
Ketamine has garnered attention for its rapid efficacy in alleviating depressive symptoms in treatment-resistant depression, offering a novel mechanism as a non-monoaminergic agent. Despite its potential, limited research has explored mental health professionals' perspectives on its use. This study assesses the attitudes, knowledge, and concerns of Portuguese psychiatrists and psychologists...
Revista Portuguesa de Psiquiatria e Saúde Mental
November 27, 2022
Pedro Mota, Joana Proença Becker, Manuel João Quartilho
A perturbação de stress pós‐traumático (PSPT) é uma doença psiquiátrica comum, geralmente crónica, com severas implicações na qualidade de vida da pessoa afetada e da sua família, e que tem vindo a apresentar um crescente reconhecimento enquanto problema de Saúde Pública. Nas últimas duas décadas, estudos clínicos com 3,4‐metilenodioximetanfetamina (MDMA) têm vindo a demonstrar...
European Psychiatry
April 1, 2021
Jackelyne Gabrielle Jesus de Miranda, Mario Barbosa, I. Figueiredo et al.
Introduction Classic psychedelics have been administered in sacramental contexts since ancient times. They were of prominent interest within psychiatry and neuroscience in the 1950s to 1960s, but the association between classic psychedelics and the emerging counterculture put an end to their research. Modern research with classic psychedelics has reinitiated interest in the treatment of both...
International Journal of Psychiatry Research
2020
Pedro Mota, Pedro Macedo, Silvério Macedo
Background: Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have been the most studied and debated cannabinoids present in cannabis. The last decade has shown a notable increase in literature regarding CBD, recognizing its anti-inflammatory and neuroprotective effects. Although there is limited evidence regarding the use of CBD in psychiatric disorders’ treatment, studies so far available...